GI, Liver & Pancreas Pathology
Ali Yaghobi Joybari; Behnaz Behzadi; Payam Azadeh; Sam Alahyari
Abstract
Background & Objective: Currently, neoadjuvant chemoradiotherapy, followed by surgery, is the standard treatment for locally advanced rectal cancer. The use of induction chemotherapy for this tumor is controversial. In this study, the benefits and side effects of induction chemotherapy in locally ...
Read More
Background & Objective: Currently, neoadjuvant chemoradiotherapy, followed by surgery, is the standard treatment for locally advanced rectal cancer. The use of induction chemotherapy for this tumor is controversial. In this study, the benefits and side effects of induction chemotherapy in locally advanced rectal cancer are evaluated.Methods: Twenty-nine patients with locally advanced rectal cancer in 2018-2019 were enrolled in this study. Initially, they underwent induction chemotherapy (oxaliplatin 130 mg/m2 every 3 weeks and capecitabine 1000 mg/m2 twice a day for 14 days every 3 weeks for 2 courses). Then, neoadjuvant chemoradiotherapy (radiotherapy 50.4 Gy/28 for 5 days a week concomitant with weekly oxaliplatin 50 mg/m2, as well as capecitabine 825 mg/m2/bid on the days of radiotherapy) was administered. After 4 weeks, computed tomography (CT) scan of thorax, pelvis, and abdomen with and without contrast was performed. Total mesorectal surgery was performed 6-8 weeks after the end of radiotherapy. Four courses of adjuvant chemotherapy were applied. Pathologic complete response (pCR), margin, sphincter preservation, and adverse effects were assessed.Results: In this study, pCR was present in 6 (20.7%) patients. R0 resection was done in 96.05%. Sphincter was preserved in 44.4% of lower rectal tumors. Two patients (6.9%) did not complete adjuvant treatment. Grade 3 adverse effects were documented in 13.7% of cases during induction chemotherapy and 17.2% of cases during neoadjuvant chemoradiation. Mortality was not reported.Conclusion: Induction chemotherapy, followed by neoadjuvant chemoradiotherapy and surgery, would be an effective and safe modality in locally advanced rectal cancer.
Hematopathology
Ali Yaghobi; Payam Azadeh; Behzad Nemati Honar
Abstract
Verrucous carcinoma (VC) is a rare variant of well differentiated squamous cell carcinoma (SCC) which is usually found in oral cavity mucosa. Cutaneous verrucous carcinoma is a rare entity and in this paper we report a 43 years old man with VC superimposed on chronically inflamed skin of ileostomy site. ...
Read More
Verrucous carcinoma (VC) is a rare variant of well differentiated squamous cell carcinoma (SCC) which is usually found in oral cavity mucosa. Cutaneous verrucous carcinoma is a rare entity and in this paper we report a 43 years old man with VC superimposed on chronically inflamed skin of ileostomy site. Previously, he was operated to treat rectal adenocarcinoma and has had ileostomy for six months. The skin lesion was resected totally during surgical operation for ileostomy closure. Histopathologic examination confirmed the diagnosis of cutaneous verrucous carcinoma. Post-operative follow up shows no evidence of recurrence after six months. We suggest patient’s training for follow up visits in order to early detection of osteomy site complications including neoplastic changes.
Hematopathology
Payam Azadeh; Nasser Rakhashni; Ali Yaghobi Joybari; Pegah Gorji Bayani; Samaneh Sarbaz; Maryam Farasatinasab
Volume 11, Issue 5 , October 2016, , Pages 439-442
Abstract
The oral cavity is uncommon site for metastatic disease usually discovered secondary to malignancy. We encountered with a rare case in which metastasis to mandibular bone was the first clinical sign in the diagnosis of breast cancer without any radiographic findings. A 49-yr-old premenopausal woman, ...
Read More
The oral cavity is uncommon site for metastatic disease usually discovered secondary to malignancy. We encountered with a rare case in which metastasis to mandibular bone was the first clinical sign in the diagnosis of breast cancer without any radiographic findings. A 49-yr-old premenopausal woman, was referred to the Department of Medical Oncology of Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran in 2014, presented with pain and tenderness in the left mandibular and temporal bone and paresthesia of the lower left lip and chin. CT scan of mandible showed no significant finding. Four months later, she was referred with complaints left breast pain for 4 wk and worsening swelling, pain and paresthesia. Breast examination revealed a 2 cm firm nodule on the left breast. Based on her medical history and histopathological study, metastatic carcinoma of the breast was suspected. She has received chemoradiotherapy that led to complete relief of her symptoms and remission of the disease. In the presence of an ambiguous sign in oral cavity such as jaw pain or paresthesia, diagnostic examination of malignancy is recommended.
Payam Azadeh; Ali Yaghobi Joybari; Samaneh Sarbaz; Hosein Ali Ghiasi; Maryam Farasatinasab
Volume 11, Issue 1 , January 2016, , Pages 76-79
Abstract
Metastasis of gastroesphageal junction (GEJ) adenocarcinoma in skeletal muscle is rare and primary sites for skeletal muscle metastases are usually lung, renal and colorectal cancer. We have encountered with the first case report of solitary psoas muscle metastasis of GEJ adenocarcinoma. Here we describe ...
Read More
Metastasis of gastroesphageal junction (GEJ) adenocarcinoma in skeletal muscle is rare and primary sites for skeletal muscle metastases are usually lung, renal and colorectal cancer. We have encountered with the first case report of solitary psoas muscle metastasis of GEJ adenocarcinoma. Here we describe a 65 years old man was diagnosed with GEJ adenocarcinoma in tertiary hospital, Tehran, Iran in February 2014. We were not able to use PET techniques due to lack of access. Staging CT scans demonstrated a small mass lateral to right psoas muscle. A CT-guided core needle biopsy of right psoas muscle was performed that supported a diagnosis of adenocarcinoma consistent with primary adenocarcinoma of the GEJ. Distant metastasis to skeletal muscle rarely occurs in patients with GEJ adenocarcinoma, but heightened awareness to these soft tissue lesions is warranted. CT or MR imaging could show findings suggestive of metastatic disease, although PET is preferable modality.
Ali Yaghoubi; Payam Azadeh; KhosroM M Sheibani; Mohammad Foudazi; Behrouz Shafaghi; Manouchehr Davaei
Volume 6, Issue 3 , June 2011, , Pages 110-116
Abstract
Background and Objectives: To compare pathologic complete response (pCR) in patients with advanced rectal cancer receiving neoadjuvant chemoradiotherapy (NACT) by 5-FU or Xeloda (capecitabine) with and without Eloxatin (oxaloplatin injection).
Materials and Methods: Seventy-five consecutive ...
Read More
Background and Objectives: To compare pathologic complete response (pCR) in patients with advanced rectal cancer receiving neoadjuvant chemoradiotherapy (NACT) by 5-FU or Xeloda (capecitabine) with and without Eloxatin (oxaloplatin injection).
Materials and Methods: Seventy-five consecutive patients with the diagnosis of advanced rectal adenocarcinoma were included. Two basic chemotherapy regimens were used: one drug (5-FU or Xeloda) or two-drug (5-U or Xeloda with Eloxatin). Endpoints were pCR and preservation of sphincter during surgery through low anterior resection (LAR). All analyses were done using SPSS software version 17.0 (SPSS Inc., Chicago, IL).
Results: There were no significant differences between the group of patients who received one-drug regimen with those who received two-drug regimen regarding the pCR (four cases (23.5%) versus 25 vases (43.1%)) state or the type of surgery performed [nine cases (52.9%) versus 36 cases (62.1%)].
Conclusion: Adding Eloxatin to the standard treatment of rectal adenocarcinoma (5-FU based) did not yield in a higher pCR or a higher chance to preserve the anal sphincter.
Ali Yaghobi; Payam Azadeh; Sh . Moghadam; Behrouz Shafaghi
Volume 5, Issue 1 , January 2010, , Pages 43-46
Abstract
Although most breast cancers are adenocarcinomas of the mammary gland, primary breast sarcomas may also arise from mammary gland mesenchymal tissue. Sarcomas represent less than 1% of primary breast neoplasms. These tumors are at high risk of recurrence and are known to have poor prognosis. Surgical ...
Read More
Although most breast cancers are adenocarcinomas of the mammary gland, primary breast sarcomas may also arise from mammary gland mesenchymal tissue. Sarcomas represent less than 1% of primary breast neoplasms. These tumors are at high risk of recurrence and are known to have poor prognosis. Surgical resection is the primary treatment for these lesions and axillary lymph node dissection is not routinely indicated in the setting of a clinically negative axilla. In this report, we introduce a patient with breast stromal sarcoma based on surgical pathology that has experienced axillary lymph node recurrence later during follow up period.
Robab Anbiaee; Payam Azadeh; Abdollah Fazlalizadeh
Volume 1, Issue 3 , June 2006, , Pages 105-108
Abstract
Background and Objective: It is well known that menstrual period and ovarian function are affected by chemotherapy. Although breast cancer is the most common cause of chemotherapy in women and ovarian hormones have very important direct and indirect effects on overall survival, disease-free survival, ...
Read More
Background and Objective: It is well known that menstrual period and ovarian function are affected by chemotherapy. Although breast cancer is the most common cause of chemotherapy in women and ovarian hormones have very important direct and indirect effects on overall survival, disease-free survival, and life quality of patients, but few studies have addressed the frequency and related factors of ovarian failure in breast cancer patients after receiving conventional regimens of chemotherapy. Therefore, the risk of ovarian failure after conventional chemotherapy regimens for breast cancer (with and without taxans) and the factors that influence ovarian function due to chemotherapy including patient’s age and type and dosage of drugs were investigated in this study. Materials and Methods: The cross sectional protocol of this study was conducted on 81 premenopausal breast cancer patients with regular menstruation that were candidates for chemotherapy and had not any history of prior hormonal therapy or chemotherapy. Alteration of menstrual cycles and ovarian function were evaluated by measuring blood levels of FSH and LH. Then, the role of patient’s age, type and dosage of drugs were analyzed on ovarian function. Results: Out of a total of 81 patients evaluated, 44 (54.3%) were found to suffer from ovarian failure after chemotherapy. There was also no significant difference for the risk of ovarian failure between two major groups of chemotherapy regimens. In addition, the probability of ovarian failure increased after increasing the dosage of the drug. Meanwhile, patients over 40 years were more sensitive to chemotherapy than younger ones. Conclusion: It is concluded that patient’s age is the most important factor determining the risk of chemical castration. In this respect, addition of taxans to conventional chemotherapy does not increase the risk of chemical castration.